You are here

Spinraza

Spinal Muscular Atrophy: Four trials to watch over the next 12 months

Spinal Muscular Atrophy: Four trials to watch over the next 12 months

Clinical Trials Arena

clinical trials

spinal muscular atrophy

Flag link:

Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza

Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza

Fierce Pharma

Alcyone Therapeutics

Flag link:

Biogen Announces New Spinraza Data Ahead of Presentation

Biogen Announces New Spinraza Data Ahead of Presentation

BioSpace

spinal muscular atrophy

Flag link:

Biogen brings in a successor to Spinraza

Biogen brings in a successor to Spinraza

BioPharma Dive

Ionis Pharmaceuticals

spinal muscular atrophy

Flag link:

Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial

Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial

Fierce Pharma

spinal muscular atrophy

Flag link:

Zolgensma flatlines, but Spinraza isn’t the beneficiary

Zolgensma flatlines, but Spinraza isn’t the beneficiary

EP Vantage

Flag link:

Biogen Reports New Spinraza Data in SMA

Biogen Reports New Spinraza Data in SMA

Global Genes

Flag link:

2 Fumbles and 1 Gift in Biogen's Latest Earnings Report

2 Fumbles and 1 Gift in Biogen's Latest Earnings Report

Motley Fool

Flag link:

Biogen is running out of safety nets

Biogen is running out of safety nets

BioPharma Dive

Flag link:

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

BioPharma Dive

spinal muscular atrophy

Flag link:

Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”

Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”

BioSpace

spinal muscular atrophy

clinical trials

Flag link:

Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

MedCity News

clinical trials

spinal muscular atrophy

Flag link:

Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients

Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients

BioSpace

clinical trials

Flag link:

Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst

Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst

Fierce Pharma

Flag link:

Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents

Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents

Fierce Pharma

Flag link:

Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis

Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis

Endpoints

PTC Therapeutics

Flag link:

Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed

Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed

Investors Business Daily

Wave Life Sciences

Jazz Pharmaceuticals

Flag link:

Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial

Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial

Fierce Pharma

clinical trials

spinal muscular atrophy

Flag link:

Threats to Spinraza are mounting, but Biogen still has cards to play

Threats to Spinraza are mounting, but Biogen still has cards to play

EP Vantage

Flag link:

Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma

Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma

Fierce Biotech

PTC Therapeutics

spinal muscular atrophy

Flag link:

Pages